Literature DB >> 28394746

Stochasticity among Antibiotic-Resistance Profiles of Common Burn-Related Pathogens over a Six-Year Period.

Zachary J Collier1, Lawrence J Gottlieb1,2, John C Alverdy1,2.   

Abstract

BACKGROUND: One of the most significant contributors to morbidity and death in patients with burns is infection, which accounts for 30%-75% of post-burn fatalities. Because of concerns for the development of antibiotic resistance in burn-related pathogens, the aims of this study were to identify antibiotic resistance trends for the four most common burn-related pathogens over a six-year period. PATIENTS AND METHODS: The study used prospectively collected and de-identified aggregate data for all burn patients admitted to the burn unit between 2009 and 2014. The database query included patient demographics along with all data regarding cultures from any source (wound, sputum, urine, stool, blood), which included isolated pathogens and antibiotic resistance profiles. Profiles were then constructed using mean inhibitory concentration standards to determine whether each pathogen was susceptible (S), intermediate (I), or resistant (R) to each antibiotic. The aggregated data were then used to construct a heat map for the four most common pathogens and their resistance profiles over the six-year study period.
RESULTS: There were 368 patients with burns (248 with positive cultures, 120 with negative cultures) in this study. The positive culture group was significantly older (38 vs. 25 y, p < 0.001) and had longer hospitalizations (17 vs. 11 d, p < 0.01) compared with the negative group. Analysis of antibiotic resistance heat maps constructed for the four most commonly isolated pathogens (methicillin-sensitive Staphylococcus aureus, Enterococcus faecalis, methicillin-resistant S. aureus, Pseudomonas aeruginosa) indicated a lack of notable resistance patterns for any of the individual pathogens.
CONCLUSIONS: Taken together, these results indicate that there are no discernible patterns of antibiotic resistance across time (six years) for the four most common burn-related pathogens. We conclude that antibiotic choice in burn patients based on previous in-hospital trends may be a flawed strategy. Emerging genomic technology to deliver point-of-care pathogen-specific antibiotic sensitivities via polymerase chain reaction may be needed to more appropriately guide antibiotic choice.

Entities:  

Keywords:  Enterococcus faecalis; Pseudomonas aeruginosa; Staphylococcus aureus; antimicrobial management; burn sepsis

Mesh:

Substances:

Year:  2017        PMID: 28394746      PMCID: PMC8881957          DOI: 10.1089/sur.2016.191

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  44 in total

1.  Predicting mortality in burn patients with bacteraemia.

Authors:  Alexandra Ceniceros; Sonia Pértega; Rita Galeiras; Mónica Mourelo; Eugenia López; Javier Broullón; Dolores Sousa; David Freire
Journal:  Infection       Date:  2015-10-08       Impact factor: 3.553

Review 2.  Association between antimicrobial resistance and virulence in Escherichia coli.

Authors:  Gabriela Jorge Da Silva; Nuno Mendonça
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

3.  Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit.

Authors:  P R Hsueh; L J Teng; P C Yang; Y C Chen; S W Ho; K T Luh
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

Review 4.  Anaerobes in burn-wound infections.

Authors:  P M Murray; S M Finegold
Journal:  Rev Infect Dis       Date:  1984 Mar-Apr

Review 5.  Prophylactic antibiotics for burns patients: systematic review and meta-analysis.

Authors:  Tomer Avni; Ariela Levcovich; Dean D Ad-El; Leonard Leibovici; Mical Paul
Journal:  BMJ       Date:  2010-02-15

6.  Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium.

Authors:  Morten Helms; Jacob Simonsen; Kare Molbak
Journal:  J Infect Dis       Date:  2004-09-21       Impact factor: 5.226

Review 7.  Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria.

Authors:  P M Bennett
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

8.  Aerobic and anaerobic bacterial flora of burns in children.

Authors:  I Brook; J G Randolph
Journal:  J Trauma       Date:  1981-04

9.  Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa.

Authors:  Bartolomé Moya; Carlos Juan; Sebastián Albertí; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

10.  Overexpression of the Shigella flexneri genes coding for DNA topoisomerase IV compensates for loss of DNA topoisomerase I: effect on virulence gene expression.

Authors:  E McNairn; N Ni Bhriain; C J Dorman
Journal:  Mol Microbiol       Date:  1995-02       Impact factor: 3.501

View more
  4 in total

Review 1.  Management and prevention of drug resistant infections in burn patients.

Authors:  Roohi Vinaik; Dalia Barayan; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Expert Rev Anti Infect Ther       Date:  2019-08-04       Impact factor: 5.091

2.  A systematic review and meta-analysis of antibiotic prophylaxis in skin graft surgery: A protocol.

Authors:  Mimi R Borrelli; Vikram Sinha; Madeleine L Landin; Maria Chicco; Kezia Echlin; Riaz A Agha; Alastair MacKenzie Ross
Journal:  Int J Surg Protoc       Date:  2019-02-28

3.  The Impact of a Multidisciplinary Approach Protocol and Integrated Guidelines for Antibiotic Prophylaxis in Plastic Surgery Procedures.

Authors:  Isa AlAlwani; Hasan AlTahoo; Fatima Yaqoob; Fatema Ahmed Ali; Sadeq Alekri
Journal:  World J Plast Surg       Date:  2021-09

Review 4.  Selective Intestinal Decontamination as a Method for Preventing Infectious Complications (Review).

Authors:  A L Barsuk; E S Nekaeva; L V Lovtsova; A L Urakov
Journal:  Sovrem Tekhnologii Med       Date:  2020-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.